We previously also reported that FGF9 bound and activated FGFR2 to promote the ERK1/2 and Rb/E2F1 pathways, and subsequently increased the expression of cyclins and CDKs to enhance cell proliferation and tumor growth both in vitro and in vivo [31]. The gene discussed is E2F1; the disease is neoplasm.